# A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr

Source: https://onco.cc/trials/nct06096779/  
OnCo record `nct06096779` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Genentech, Inc., active and no longer recruiting.

## Summary

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis is a phase 2 interventional study registered as NCT06096779 by Genentech, Inc., with 30 participants enrolled, started 2024-07-15 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06096779
- Phase: 2
- Setting: A Phase II, Open-label, Multi-cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
- Sponsor: Genentech, Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06096779: https://clinicaltrials.gov/study/NCT06096779

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct06096779.json